Watrium invests in Sensio AS together with Sensio’s majority owner Longship. Sensio has recently acquired Safecall Aps, Vestfold Audio, Hospital IT and Roommate As. The proceeds from the placement will...
28th June 2021
Watrium supports CMR Surgical in largest ever MedTech financing round Watrium supports CMR Surgical in the 600m Series D funding round, the largest ever MedTech private financing round worldwide. The...
5th February 2021
Watrium continues its support of London AIM-listed Distribution Finance Capital Holdings Plc (“DF Capital”) through participation in a GBP 40 million private placement. DF Capital was recently awarded their banking licence. The net proceeds of the private placement...
29th September 2020
Distribution Finance Capital Holdings plc, a niche lender providing working capital solutions to dealers and manufacturers across the UK, today announces that, following the resubmission of its banking licence application in August...
23rd September 2020
While Watrium refurbish its headquarters at Kanalen 5, Tjuvholmen in Oslo, Norway, the company will temporarily move to its Oslo Atrium office building at Dronning Eufemias gate 6A in Bjørvika in...
29th June 2020
2019 was an eventful year for Watrium, with several exciting new investments, overall strong development for the portfolio companies, attractive and well positioned real estate assets, and moving into 2020 from a position of strength with a robust balance sheet. The continued value creation from...
28th May 2020
Watrium continues its support of Oslo-listed Ultimovacs ASA through participation in a NOK 160 million private placement in the pharmaceutical company. Ultimovacs is developing novel immunotherapies against cancer. The net...
27th September 2019
CMR Surgical Limited, the Company developing, manufacturing and marketing the next-generation surgical robotic system, Versius®, has raised £195 million ($240 million) to fully fund the global commercialisation of the business.
3rd June 2019
Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer. The lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen...
9th May 2019
Watrium supports the listing of DF Capital on AIM as cornerstone investor.
